Domov › Akútna myeloidná leukémia › Kalifornia › Orange
Klinické štúdie Akútna myeloidná leukémia v meste Orange, CA
13 štúdií pre Akútna myeloidná leukémia hľadá účastníkov v zariadeniach v meste Orange a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Prebieha náborFáza 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Prebieha náborFáza 2
- UCI Health Chao Family Comprehensive Cancer Center, Orange
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Prebieha náborFáza 3
- Children's Hospital of Orange County, Orange
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Prebieha náborFáza 1/2
- Children's Hospital of Orange County, Orange
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Prebieha náborFáza 1
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Prebieha náborFáza 3
- Children's Hospital of Orange County Main Campus - Orange, Orange
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Prebieha náborFáza 3
- University of California, Irvine, Orange
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Prebieha náborFáza 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Prebieha náborFáza 1
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Prebieha náborFáza 4
- UCI Irvine Health, Orange
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Prebieha náborObservačná štúdia
- Children's Hospital of Orange County (CHOC), Orange
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Prebieha náborFáza 2/3
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Prebieha náborFáza 1
- UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
Štúdie Akútna myeloidná leukémia v iných mestách
- Houston, TX85 štúdií
- New York City, NY51 štúdií
- Boston, MA44 štúdií
- Seattle, WA41 štúdií
- Baldwin Park, CA40 štúdií
- Columbus, OH35 štúdií
- Philadelphia, PA34 štúdií
- Durham, NC33 štúdií
- Atlanta, GA31 štúdií
- Tampa, FL29 štúdií
- Chicago, IL26 štúdií
- Portland, OR25 štúdií
Iné štúdie v Orange
- Nemalobunkový karcinóm pľúc25 štúdií
- Metastatická rakovina20 štúdií
- Kolorektálny karcinóm16 štúdií
- Rakovina vaječníkov16 štúdií
- Rakovina pankreasu15 štúdií
- Melanóm14 štúdií
- Rakovina pečene (hepatocelulárny karcinóm)14 štúdií
- Rakovina prsníka14 štúdií
- Rakovina pľúc14 štúdií
- Rakovina prostaty14 štúdií
- Rakovina žalúdka13 štúdií
- Rakovina (všetky typy)13 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.